By partnering with AFT and Qianshou, ZHAOKE OPHTH-B(06622) is pushing forward the commercialization process of BRIMOCHOL PF for the treatment of presbyopia in Singapore and Vietnam.

ZHAOKE OPHTH-B (06622) announces that the company has expanded its partnership agreement with leading healthcare product manufacturer and distributor AFT Pharmaceuticals Limited (AFT) to commercialize BRIMOCHOL PF in Singapore. The company has also established a strategic partnership with leading Asian ophthalmic company Senju Pharmaceutical Co., Ltd. (Senju) to commercialize the product in Vietnam. ZHAOKE has granted AFT and Senju exclusive distribution rights in Singapore and Vietnam, including the rights to register, import, promote, distribute, market, and sell BRIMOCHOL PF in the respective markets. Through these agreements, AFT and Senju become the seventh and eighth commercialization partners for BRIMOCHOL PF, demonstrating the company's commitment to global expansion. BRIMOCHOL PF is a potential therapy for correcting near vision loss due to presbyopia, acquired by the company through its partner Tenpoint Therapeutics, Ltd. (Tenpoint). Tenpoint is a global biotechnology company developing breakthrough therapies to restore vision in aging eyes. In June 2025, Tenpoint announced that the US FDA had accepted the new drug application for the drug. FDA has set a Prescription Drug User Fee Act (PDUFA) review deadline for BRIMOCHOL PF of January 28, 2026.